Analyst consensus rating
BioAge Labs Analyst Rating: Buy
Direct answer
BioAge Labs's consensus rating is Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $32.56.
Forecast evidence checked October 18, 2026.
Get free BioAge Labs email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.84
- Average price target
- $32.56
- High price target
- $73.00
- Low price target
- $8.00
- Low target gap
- +65.3%
- Target upside
- +572.6%
- High target gap
- +1,408.3%
- Target range width
- 1,343%
- Consensus rating
- Buy
- Analysts
- 9
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BioAge Labs?
BioAge Labs has a verified Buy consensus. The same dataset has an average price target of $32.56.
How far are BioAge Labs's low and high targets from the recorded price?
The low target implies +65.3%, while the high target implies +1,408.3%.
How many analysts are included in BioAge Labs's consensus?
The verified consensus includes 9 analysts.
How is BioAge Labs's target upside or downside calculated?
The average target of $32.56 is divided by the recorded price of $4.84, then one is subtracted to produce +572.6%. This does not guarantee a future return.
When was BioAge Labs's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.